NCT05171387 2025-06-22Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate CancerBayerPhase 2 Completed78 enrolled
NCT06765954 2025-05-06Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.ImmunityBio, Inc.Phase 2 Not yet recruiting20 enrolled
NCT02217566 2020-01-13Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol TherapyJanssen Research & Development, LLCPhase 2 Completed46 enrolled 13 charts